Comparison of pyritinol and auranofin in the treatment of rheumatoid arthritis.

Lemmel EM.

Staatliches Rheumakrankenhaus, Baden-Baden, Germany.
Br J Rheumatol 1993 May;32(5):375-82

ABSTRACT

The efficacy and tolerability of pyritinol (PY) and auranofin (AU) were compared in a multicentre double-blind study.  Patients with RA received 600 mg/day PY or 6 mg/day AU for 1 year.  Response was rated by a defined improvement in at least four of the following:  Ritchie index, joint swelling index, rating scales for pain and general well-being, functional index, morning stiffness, ESR.  Of the 139 fully evaluable PY patients 61 (44%) dropped out due to adverse events or response failure compared with 44 (31%) of the 142 AU patients. In patients treated for 1 year efficacy parameters improved more in the PY than in the AU group, with significant differences for the general well-being (P = 0.022), ESR (P = 0.029) and haemoglobin (P = 0.0042).  The response rate for PY (61/78 patients, 78%) was significantly superior to AU (58/98 patients, 59% P = 0.009).  An intention-to-treat analysis corroborated this result (P = 0.030).  Adverse events (AE) occurred in 64% of PY patients and in 58% of AU patients: main AE were mucocutaneous symptoms (PY 36%, AU 23%) and gastrointestinal complaints (PY 30% AU 37%). Single cases of proteinuria, hepatic and haematological abnormalities were noted in both groups

1.  Pyritinol on the clinical course of traumatic coma
2.  Effect of pyritinol on sequelae of head injuries.
3.  Pyritinol in the treatment of rheumatoid arthritis
4.  Psychopharmacological effects of Pyritinol
5.  Pyritinol as a free radical scavenger
6.  Pyritinol's effect on brain blood flow in dementia patients
7.  Stimulation of neutrophil functions by Pyritinol
8.  Pyritinol's effect on senile dementia of the Alzheimer type
9.  Pyritinol's effect on advanced dementia